Why did GAAP net loss increase even though operating performance improved?

The increase was driven by non-operating items rather than core operations. Unrealized losses on the company's marketable equity security investment were $15.5 million in Q2 2024 versus a $64.0 million gain in Q2 2023, a $79.5 million swing. This was partially offset by a prior-year $23.6 million impairment that did not recur and a $19.0 million improvement in loss from operations. Non-GAAP net loss, which excludes these items, improved to $58.5 million from $88.7 million.

What drove the revenue growth, and is it sustainable?

Growth came from both volume and price. Clinical testing volume rose 14% and biopharma testing volume rose 56%, while higher Medicare reimbursement for Guardant360 LDT ($5,000 effective January 1, 2024) and better Medicare Advantage and commercial payer rates lifted average selling prices. The raised guidance suggests management expects continued momentum, though investors should monitor whether reimbursement tailwinds persist and whether biopharma volume, which is more lumpy, remains strong.

Is the company moving toward profitability and cash-flow breakeven?

Progress is visible but not yet complete. Adjusted EBITDA loss narrowed substantially and non-GAAP operating expenses are guided flat to down 1% for 2024. However, free cash flow is still deeply negative, with 2024 guidance of $(275)-$(285) million, an improvement of $60-$70 million over 2023. Investors should expect continued cash burn in 2024, and the company's $1.0 billion cash balance provides a runway but not an imminent path to self-funding.

Why did development services revenue and margin decline?

Development services and other revenue fell to $10.7 million from $11.9 million, and its gross margin dropped to 37% from 62%. The filing does not provide a detailed explanation for the margin decline in this excerpt, so investors should review the company's 10-Q for the drivers. The segment is small relative to total revenue, so its impact on overall results is limited.

GH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.

Guardant Health (Nasdaq: GH) reported second quarter 2024 results on August 7, 2024, with total revenue of $177.2 million^a, up 29% year over year from $137.2 million.

Precision oncology revenue grew 33% to $166.5 million^b, driven by clinical test volume growth of 14% and biopharma test volume growth of 56%, plus higher Medicare reimbursement for Guardant360 LDT ($5,000, effective January 1, 2024) and improved Medicare Advantage and commercial payer rates. Development services revenue declined to $10.7 million from $11.9 million. GAAP gross margin was 59% versus 61% a year earlier, and non-GAAP gross margin was 60% versus 62%, with development services margin compressing sharply to 37% from 62%.

GAAP net loss widened to $102.6 million^c ($0.84 per share) from $72.8 million ($0.67 per share), primarily because of a $79.5 million year-over-year increase in unrealized losses on the company's equity security investment, which offset a prior-year $23.6 million impairment and a $19.0 million improvement in operating loss. Non-GAAP net loss narrowed to $58.5 million ($0.48 per share) from $88.7 million ($0.82 per share). Adjusted EBITDA loss improved to $61.9 million from $85.2 million, and free cash flow was $(99.1) million versus $(100.5) million, with $1.0 billion in cash, cash equivalents and restricted cash at June 30, 2024.

Management raised full-year 2024 revenue guidance excluding screening to $690^d-$700 million (22%-24% growth) from $675-$685 million, while reaffirming non-GAAP gross margin excluding screening of 61%-63%, non-GAAP operating expenses of $720-$730 million, and free cash flow of $(275)-$(285) million. The quarter also included FDA approval of Shield as a first-line colorectal cancer screening option, the commercial launch of Shield IVD, and Medicare coverage covering roughly 45 million eligible individuals.

02—Key points

Key Highlights

Total revenue rose 29% to $177.2 million, with precision oncology revenue up 33% to $166.5 million on clinical (+14%) and biopharma (+56%) volume growth and higher Guardant360 reimbursement.
Full-year 2024 revenue guidance excluding screening was raised to $690-$700 million, up from $675-$685 million, implying 22%-24% growth.
GAAP net loss widened to $102.6 million ($0.84/share) from $72.8 million, driven mainly by a $79.5 million swing in unrealized losses on an equity investment; non-GAAP net loss improved to $58.5 million from $88.7 million.
Adjusted EBITDA loss narrowed to $61.9 million from $85.2 million, a meaningful operational improvement year over year.
Gross margin contracted modestly: GAAP gross margin fell to 59% from 61%, and development services gross margin dropped to 37% from 62%.
Free cash flow of $(99.1) million was roughly flat year over year, and the company held $1.0 billion in cash and equivalents at June 30, 2024, against $1.14 billion in convertible senior notes outstanding.
FDA approval of Shield for first-line CRC screening and its Medicare coverage for about 45 million eligible individuals expand the company's screening opportunity.

03—Questions

Frequently Asked Questions

Why did GAAP net loss increase even though operating performance improved?
The increase was driven by non-operating items rather than core operations. Unrealized losses on the company's marketable equity security investment were $15.5 million in Q2 2024 versus a $64.0 million gain in Q2 2023, a $79.5 million swing. This was partially offset by a prior-year $23.6 million impairment that did not recur and a $19.0 million improvement in loss from operations. Non-GAAP net loss, which excludes these items, improved to $58.5 million from $88.7 million.
What drove the revenue growth, and is it sustainable?
Growth came from both volume and price. Clinical testing volume rose 14% and biopharma testing volume rose 56%, while higher Medicare reimbursement for Guardant360 LDT ($5,000 effective January 1, 2024) and better Medicare Advantage and commercial payer rates lifted average selling prices. The raised guidance suggests management expects continued momentum, though investors should monitor whether reimbursement tailwinds persist and whether biopharma volume, which is more lumpy, remains strong.
Is the company moving toward profitability and cash-flow breakeven?
Progress is visible but not yet complete. Adjusted EBITDA loss narrowed substantially and non-GAAP operating expenses are guided flat to down 1% for 2024. However, free cash flow is still deeply negative, with 2024 guidance of $(275)-$(285) million, an improvement of $60-$70 million over 2023. Investors should expect continued cash burn in 2024, and the company's $1.0 billion cash balance provides a runway but not an imminent path to self-funding.
Why did development services revenue and margin decline?
Development services and other revenue fell to $10.7 million from $11.9 million, and its gross margin dropped to 37% from 62%. The filing does not provide a detailed explanation for the margin decline in this excerpt, so investors should review the company's 10-Q for the drivers. The segment is small relative to total revenue, so its impact on overall results is limited.

04—Continue

← View all 8-K filings